Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 2/20 | 0.46 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | TOP2A | P11388 | 2/20 | 0.40 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.40 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20550584 | 1.00 | ATM (0.47) | ATMBTKTNK2ELANETOP2A | |
| SCHEMBL14630351 | 0.87 | BTK (0.58) | ATMBTKTNK2 | |
| SCHEMBL18849710 | 0.83 | BTK (0.41) | BTKTNK2 | |
| SCHEMBL20550691 | 0.83 | BTK (0.41) | BTKTNK2 | |
| SCHEMBL30468175 | 0.81 | TNK2 (0.48) | BTKTNK2 | |
| SCHEMBL28623986 | 0.81 | BTK (0.42) | BTKTNK2 | |
| SCHEMBL14636369 | 0.81 | BTK (0.42) | BTKTNK2 | |
| SCHEMBL17899460 | 0.76 | BTK (0.37) | BTKTNK2 | |
| SCHEMBL27929118 | 0.74 | ATM (0.55) | ATMELANECTRB1 | |
| SCHEMBL27929117 | 0.74 | ATM (0.55) | ATMELANECTRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11110088-B2 | Imidazopyrazine inhibitors of Bruton's tyrosine kinase | ACERTA PHARMA B.V. (NL) | 2021-09-07 | — | — | US | disclosed |
| EP-3865485-A1 | IMIDAZOPYRAZINE INHIBITORS OF BRUTON'S TYROSINE KINASE | Acerta Pharma B.V. (NL) | 2021-08-18 | — | — | EP | disclosed |
| US-20200330461-A1 | Imidazopyrazine Inhibitors of Bruton's Tyrosine Kinase | ACERTA PHARMA B.V. (NL) | 2020-10-22 | — | — | US | disclosed |
| US-10736893-B2 | Imidazopyrazine inhibitors of Bruton's tyrosine kinase | ACERTA PHARMA B.V. (NL) | 2020-08-11 | — | — | US | disclosed |
| US-10736893-B2 | Imidazopyrazine inhibitors of Bruton's tyrosine kinase | ACERTA PHARMA B.V. (NL) | 2020-08-11 | — | — | US | disclosed |
| US-20180318297-A1 | Imidazopyrazine Inhibitors of Bruton's Tyrosine Kinase | ACERTA PHARMA B.V. (NL) | 2018-11-08 | — | — | US | disclosed |
| WO-2017077507-A1 | IMIDAZOPYRAZINE INHIBITORS OF BRUTON'S TYROSINE KINASE | ACERTA PHARMA B.V. (NL) | 2017-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10736893-B2 | Imidazopyrazine inhibitors of Bruton's tyrosine kinase | BTK, LCK, SYK | ATM 782/4885BTK 1/4885TNK2 256/4885 |
| US-20200330461-A1 | Imidazopyrazine Inhibitors of Bruton's Tyrosine Kinase | BTK, LCK, SYK | ATM 782/4885BTK 1/4885TNK2 256/4885 |
| US-20180318297-A1 | Imidazopyrazine Inhibitors of Bruton's Tyrosine Kinase | BTK, LCK, SYK | ATM 782/4885BTK 1/4885TNK2 256/4885 |
| US-11110088-B2 | Imidazopyrazine inhibitors of Bruton's tyrosine kinase | BTK, LCK, SYK | ATM 782/4885BTK 1/4885TNK2 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.